Treatment options and patient perspectives in the management of fibromyalgia: future trends

Kim Lawson
Biomedical Research Centre, Sheffield
Hallam University, Faculty of Health and Wellbeing, Sheffield, UK

Abstract: Fibromyalgia (FM) is a common, complex, and difficult to treat chronic widespread pain disorder, which usually requires a multidisciplinary approach using both pharmacological and non-pharmacological (education and exercise) interventions. It is a condition of heightened generalized sensitization to sensory input presenting as a complex of symptoms including pain, sleep dysfunction, and fatigue, where the pathophysiology could include dysfunction of the central nervous system pain modulatory systems, dysfunction of the neuroendocrine system, and dysautonomia. A cyclic model of the pathophysiological processes is compatible with the interrelationship of primary symptoms and the array of postulated triggers associated with FM. Many of the molecular targets of current and emerging drugs used to treat FM have been focused to the management of discrete symptoms rather than the condition. Recently, drugs (eg, pregabalin, duloxetine, milnacipran, sodium oxybate) have been identified that demonstrate a multidimensional efficacy in this condition. Although the complexity of FM suggests that monotherapy, non-pharmacological or pharmacological, will not adequately address the condition, the outcomes from recent clinical trials are providing important clues for treatment guidelines, improved diagnosis, and condition-focused therapies.

Keywords: fibromyalgia, pain, sleep dysfunction, fatigue, exercise, pharmacological treatments

Introduction
Fibromyalgia (FM) is a common chronic widespread pain condition in which patients typically present with allodynia and hyperalgesia in addition to experiencing many auxiliary symptoms (Table 1) (Wolfe et al 1990; Clauw 1995; Jain et al 2003). The American College of Rheumatology (ACR) criteria for the classification of FM established in 1990 require a history of widespread pain for at least 3 months and tenderness, determined by a force of 4 kg, in at least 11 of 18 defined tender points (Wolfe et al 1990). The presence and severity of FM, which is often reliant on the patient’s self-reported symptoms, cannot be determined by objective clinical findings, radiographic abnormalities or routinely used laboratory tests (Mease 2005; Arnold 2006). Localized or regional pain in most patients with FM precedes the widespread pain, which could suggest the latter develops from the former. Although pain is often considered the predominant feature, FM is a complex and difficult to treat chronic condition that usually requires a multidisciplinary approach using both pharmacological and non-pharmacological management. Classification and treatment of FM is often further complicated by a waxing and waning course of the symptoms being typical and the presence of co-morbid conditions (Table 2).

Many of the symptoms (fatigue, sleep dysfunction, stiffness, depression, anxiety, cognitive disturbance) reported in clinical practice in addition to the pain and tenderness, however, present a condition with a complexity that is probably beyond the ACR 1990 classification (Katz et al 2006). Nevertheless based upon the ACR 1990 criteria, epidemiological studies report prevalence of the condition is...
2% to 4% of the general population, increasing to greater than 7% of those over 70 years of age (Rooks 2007). The patient population consists of a female to male ratio of 9:1, and the most common age group is 45 to 60 years. Related to this, FM has emerged over the past 20 years as a leading cause of visits to rheumatologists, either alone or as an accompaniment of other rheumatic disorders (Bennett et al 2007). Although an epidemiological study looks at the incidence, distribution, and control of a particular disease in a population, the outcomes are dependent on the clarity of definition of the condition. The complexity of FM is probably responsible for limited epidemiological data and thereby a likely underestimation where subjects presenting with FM symptoms remain undiagnosed.

A study published in 2003 examined the general health status and work incapacity, and views on the effectiveness of therapy of patients over a two-year observation period (Noller and Sprott 2003). Although there was general satisfaction with quality of life improvement and health status, despite many various treatments received, the patients with FM showed no improvement in pain. The authors suggested that the positive outcomes and satisfaction was probably the result of patient instruction and education of the disease. As a consequence of high prevalence, frequent co-morbidities, and frustration with current treatment modalities, it is increasingly evident that FM represents a significant challenge (Hoffman and Dukes 2008).

Further, symptom expression in FM tends to vary on an individual basis, indicative of heterogeneity within the condition and the possibility of subgroups of patients with FM. Several studies have suggested heterogeneity in the presentation of FM with differences in biological variables (eg, positive antinuclear antibodies, cytokine abnormalities, growth hormone, thyroid hormones) supportive of subgroups within the patient population (Bennett 1998; Al-Allaf et al 2002; Gur et al 2002; Salemi et al 2003; Metyas et al 2007). Subgroups based on responses to pharmacological interventions and psychosocial responses have also been demonstrated (Turk et al 1996; Rossy et al 1999; Wolfe et al 2000; Lawson 2006a; Lawson 2008).

### Management issues

The management of FM has been complicated by the lack of a universally accepted pathophysiological mechanism and overlap with symptoms of other health conditions (eg, chronic fatigue syndrome, myofascial pain, systemic lupus). The development of focused and mechanistically based therapeutic options targeting the array of symptoms of FM has been limited. Current management approaches of improving health status in FM use a rehabilitation model, rather than a classic biomedical model, integrating exercise, education (stress management programs, cognitive behavioral therapy (CBT)) and pharmacological treatments (Goldenberg et al 2008). Although recommendations (eg, European League Against Rheumatism (EULAR), American Pain Society (APS)) for FM management have been published (Burckhardt et al 2005; Carville et al 2008), a universally accepted treatment algorithm or approach is often lacking. A limitation for gaining consensus regarding optimal management of FM is that in the many clinical trials efficacy of the diverse set of treatments has been inconsistent with a large proportion of patients not reporting clinically significant outcomes. The guidelines published by EULAR and APS provide evidence-based considerations related to evaluation and diagnosis of FM, and non-pharmacological and pharmacological therapies (Burckhardt et al 2005; Carville et al 2008). The evidence regarding effectiveness of treatment tended to favor pharmacological studies where double blinding and placebo controls were possible. Management initially is often drug treatment (which may be as a consequence of patient preferences) plus self-management advice to pace activities and follow a regular activity program.

| **Table 1** Symptoms of fibromyalgia |
|--------------------------------------|
| Widespread pain                      |
| Hyperalgesia and allodynia           |
| Chronic fatigue                      |
| Sleep disturbance                    |
| Stiffness                            |
| Depression                           |
| Paresthesias                         |
| Cognitive disruption                 |
| Exercise intolerance                 |

| **Table 2** Examples of conditions frequently co-morbid with fibromyalgia |
|------------------------------------------------|------------------|
| Chronic low back pain                   |
| Irritable bowel syndrome                |
| Depression/anxiety                      |
| Temporomandibular joint disorder        |
| Chronic fatigue syndrome                |
| Multiple chemical sensitivities         |
| Interstitial cystitis                   |
| Rheumatoid arthritis                    |
appropriate to the individual’s need (Hammond and Freeman 2006; Goldenberg et al 2008).

There has been a rise in the development of new interventions for the treatment of FM and a variety of outcome measures have been used during clinical trials to assess improvement in patients with FM. Partly due to issues related to the classification of FM there often has not been uniform agreement as to which domains or which assessment tools should be utilized (Mease et al 2007). Often assessment of pain is a primary domain of the instrument. FM, however, has an impact on functioning in daily life from the perspective of the patient, although not all pain assessment instruments address these factors. Fatigue in FM is considered by patients to be the second most important domain after pain and may play a role of relative importance in the deterioration of the active state particularly with respect to the long duration of the symptom (Mease et al 2007). Thus, the complexity of this condition may limit in clinical practice the potential of a single instrument covering the diversity of symptoms of FM raising difficulties such as insensitivity or efficacy misinterpretation associated with the multidimensionality (Prodinger et al 2008).

**Treatment options**

Evidence supports exercise and education interventions alone and in combination offering benefit for people with FM (Burckhardt et al 2005; Busch et al 2008; Carville et al 2008); however, the content and duration of interventions and outcomes can be unpredictable. Although the number of studies of exercise or behavioral interventions and education has increased in the past decade, comparisons are limited due to a range of factors such as inconsistent outcome measures, assessment tools, small sample size, and high attrition rates (Rooks et al 2007). Good outcomes have, however, been reported with a number of forms of relaxation training including electromyography (EMG) biofeedback, heart rate variability (HRV) biofeedback, meditation-based stress reduction, tai-chi, and yoga therapy (Drexler et al 2002; Hammond and Freeman 2006; Hassett et al 2007; Goldenberg et al 2008). CBT provides improvements in pain-related behavior, coping strategies and overall physical function in patients with FM (Turk et al 1998; Nielson and Jensen 2004; Bennett and Nelson 2006; Thieme et al 2007). Although it has been reported that benefit from CBT can be maintained for 6 months, the efficacy of this form of treatment is often found to be inconsistent and, as a single treatment modality, CBT does not offer distinct advantage over programs of education or exercise (Turk et al 1998; Kendall et al 2004; Bennett and Nelson 2006). Pretreatment patient characteristics are suggested to be important predictors of the response to CBT and thereby beneficial outcomes (Turk and Flor 1989; Thieme et al 2007).

Exercise rehabilitation has recently gained increased acceptance as a component of the symptom management for FM. Modest effects on functional and symptomatic outcomes in patients with FM have been reported with supervised aerobic exercise training such as cycle ergometry, walking, jogging, and water-based activities (Jones et al 2006; Maquet et al 2007; Busch et al 2008). These include improvements in measures of cardiovascular fitness, Fibromyalgia Impact Questionnaire (FIQ) subcales of wellbeing and sleep, psychological function, pain-pressure threshold, and participant-rated and physician-rated disease severity (Mannerkorpi, 2005; Jones et al 2006; Maquet et al 2007; Busch et al 2008). The ability to engage in long, continuous bouts of activity is often limited by the pain associated with FM, therefore alternative systems, such as interval-type training are likely to be more appealing and tolerable for this patient group. In addition, exercises and activities that strengthen the skeletal muscles (eg, stretching) that do not cause undue pain are also important for patients with FM (Jones et al 2002; Okumus et al 2006; Matsutani et al 2007; Bircan et al 2008; Busch et al 2008).

**Pharmacological therapies**

The pharmacological approach to the management of the condition has often been influenced by the debate of whether FM is a single entity or a collection of symptoms. As a consequence, drug therapy has often focused toward the individual symptoms, particularly pain, with current pharmacological treatments (Table 3) remaining largely empiric (Lawson 2006a; Lawson 2008). The failure of anti-inflammatory medications, such as the non-steroidal anti-inflammatory drugs, naproxen and ibuprofen, and prednisone to be effective treatments of FM supports a lack of underlying peripheral structural damage and inflammatory signs (Clark et al 1985; Goldenberg et al 1986; Yarus et al 1989). A sensory abnormality, with alterations in substance P levels, N-methyl-D-aspartate acid (NMDA) receptors and mono-aminergic activity within the central nervous system (CNS) of patients with FM that would be comparable with central sensitization of nociceptive afferent pathways creating a stimulus-independent pain state has been proposed (Desmeules et al 2003; Abeles et al 2007; Martinez-Lavin 2007). Clinical trials of opioid agonists as treatments of FM have been limited and often ineffective. The usefulness
of opioids in controlling FM pain may be hindered by the suggestion that the opioid systems are maximally activated or a decreased availability of central μ-opioid receptors results in a reduced efficacy in this patient group (Baraniuk et al 2004; Harris et al 2007).

Recent studies have emphasized the global state of the patient as being an important consideration with quality of life outcomes evaluation as an efficacy assessment of pharmacological therapies. This has identified the value of a number of pharmacological targets in the management of FM, in addition to offering insights to aspects of the pathophysiology of the condition.

Bioamine modulators

There appears to be a failure in patients with FM to modulate pain due to noxious stimuli because of dysfunction in the descending inhibitory pain pathways (Kosek and Hansson 1997; Staud et al 2003; Julien et al 2005). Serotonergic and norepinenergic neurons in the descending inhibitory system that links the periaqueductal gray and the rostral ventromedial medulla with the spinal cord are involved in pain regulation (Abeles et al 2007). Thus, enhancement of the activity of serotonin and norepinephrine within these structures would be expected to evoke analgesia.

Often antidepressants, particularly tricyclic antidepressants (TCAs) such as amitriptyline and dothiepin, have been first-line pharmacological therapies for FM (Arnold 2006; Lawson 2006a). Low-dose TCAs have been significantly effective in the management of sleep, pain, and fatigue in patients with FM (Carette et al 1994; Carette et al 1995; Richeimer et al 1997; Rao and Clauw 2004; Baker and Barkhuizen 2005; Mease 2005; Goldenberg 2007). Inhibition of the reuptake of serotonin and norepinephrine into the neuronal terminals of the descending tracts by low-dose TCAs has been suggested to be responsible for analgesic effect of these agents in FM. Although clinically applicable improvement in pain (>30% reduction) with TCAs was observed in randomized controlled trials (RCTs), this was often limited to 25% to 45% of FM patients given these drugs (Carette et al 1994, 1995; Richeimer et al 1997). The limited utility of TCAs as treatments of FM has been related to unpredictable responses, adverse effects, and a lack of long-term efficacy evidence.

The evaluation of selective serotonin reuptake inhibitors (SSRIs) in clinical trials with FM patients have shown mixed results (Wolfe et al 1994; Anderberg et al 2000; Arnold et al 2002; Patkar et al 2007). Agents with mixed serotonin and norepinephrine activity (eg, fluoxetine and paroxetine) have demonstrated greater efficacy in the management of FM than SSRIs with higher specificity for serotonin reuptake inhibition (eg, citalopram). The conclusion that agents with higher selective activity are less consistent as treatments of FM is supported by the finding that the combination of fluoxetine and amitriptyline was more effective (reduced pain and FIQ scores, and improved sleep) than either drug alone (Goldenberg et al 1996).

New serotonin and norepinephrine reuptake inhibitors (SNRIs; eg, duloxetine, milnacipran, venlafaxine) have become the focus of recent RCTs (Arnold 2006; Lawson 2006a). Duloxetine has a balanced inhibitory profile of serotonin and norepinephrine reuptake, while milnacipran, similarly to amitriptyline, preferentially inhibits norepinephrine reuptake, but also exhibits weak NMDA receptor inhibition (Shuto et al 1995; Stahl et al 2005). Duloxetine significantly improved measures of pain and several measures of quality of life (eg, FIQ, Clinical Global Impressions (CGI), Patient Global Impressions (PGI)) in patients with FM, with and without depression (Arnold et al 2004, 2005). The reduction of pain and improved quality of life by duloxetine were independent of the presence of depression suggesting the symptoms of

| Table 3 Examples of current pharmacological treatments of fibromyalgia |
|---------------------------------------------------------------|
| Tricyclic antidepressants (TCAs)                             |
| amitriptyline                                               |
| doxepin                                                     |
| Serotonin-norepinephrine re-uptake inhibitors (SNRIs)       |
| duloxetine                                                  |
| milnacipran                                                 |
| venlafaxine                                                 |
| Selective serotonin re-uptake inhibitors (SSRIs)            |
| fluoxetine                                                  |
| citalopram                                                  |
| Dopamine agonist                                            |
| pramipexole                                                 |
| Anti-epileptics                                             |
| pregabalin                                                  |
| gabapentin                                                  |
| Sedative hypnotics                                          |
| zopiclone                                                   |
| zolpidem                                                    |
| Analgesics                                                  |
| dihydrocodeine                                             |
| morphine                                                    |
| tramadol                                                    |
| acetaminophen                                               |
| Examples of current pharmacological treatments of fibromyalgia |
FM are not related to this mood state. Although duloxetine is an effective treatment of FM, this has predominantly been observed in female patients and a 50% decrease or greater in any pain score was only achieved in up to 41% (dependent on the treatment regime) of subjects (Arnold et al 2004, 2005). During 6 months of treatment, duloxetine demonstrated durability with outcomes superior to placebo in the improvement of pain and secondary measures such as FIQ, CGI, and Short Form 36 (SF-36) scores (Russell et al 2008). Although fatigue is a common symptom reported by patients with FM (Mease et al 2007), duloxetine failed to improve general or physical fatigue during the course of the trial. Interestingly though, a significant improvement was obtained in the mental fatigue domain suggesting that duloxetine treatment could improve the cognitive dysfunction associated with FM (Russell et al 2008).

Milnacipran relieves pain symptoms and improves measures of quality of life (eg, PGI and FIQ scores) associated with FM (Vitton et al 2004; Gendreau et al 2005). A reduction of pain by 50% or greater was observed in up to 37% of the patient population and a greater improvement in pain reduction was recorded in non-depressed subjects treated with milnacipran. These findings are consistent with the analgesic effects of milnacipran, like those of duloxetine, not being as a consequence of improvement of mood. The durable efficacy of milnacipran as a treatment of FM has been demonstrated in 15-week, 6-month, and 12-month RCTs where multidimensional symptom improvement was reported (Clauw et al 2007a, b; Goldenberg et al 2007).

The SNRIs, duloxetine and milnacipran, are well tolerated because they do not interact with adrenergic, cholinergic, or histaminergic receptors, or sodium channels and thereby lack many of the adverse effects of TCAs. It is of note, however, that insomnia was a frequently reported adverse effect for duloxetine in a condition that presents sleep dysfunction as a major symptom (Arnold et al 2004, 2005; Russell et al 2008).

Therefore, agents that modulate serotonin and norepinephrine are effective treatments for some, but not all, patients with FM. Although SNRIs are well tolerated, the observation that a significant number of patients do not gain benefit from this treatment can question the relationship of this mechanism of action and the pathophysiology of FM. A critical issue that could be addressed by other SNRIs would be the balance of the norepinephrine versus serotonin reuptake inhibition. Although modulation of serotonin and norepinephrine levels is the primary mechanism of TCAs, SSRIs, and SNRIs, these agents act on multiple nociceptive targets (eg, NMDA receptors, potassium channels) at central and peripheral locations, the contribution of which to the clinical outcomes obtained is unknown (Lawson 2002; Mico et al 2006). The NMDA receptor antagonists ketamine and dextromethorphan have demonstrated efficacy (pain score) as analgesics in the treatment of FM (Clark and Bennett 2000; Graven-Nielsen et al 2000; Cohen et al 2006). Due to a lack of specificity and thereby associated adverse effects, however, NMDA receptor antagonists are not widely accepted as treatments of chronic pain. Interestingly potassium channels, whose functional state has been studied in patients with fibromyalgia, are molecular targets for the management of pain (Lawson 2006b; Lawson et al 2008). These molecules have been developed to act optimally at sites related to the bioamine systems and not at the auxiliary targets, which could account for the lack of universal effectiveness in this patient population.

It is interesting to note that a reduction in pain and an improvement in health-related quality of life in patients with FM have been demonstrated with tramadol alone, or in combination with acetaminophen (Bennett et al 2005). The pharmacological properties of tramadol, which is included in both the EULAR and APS guidelines for FM management, are a mixture of serotonin and norepinephrine reuptake inhibition and weak μ-opioid receptor agonism (Frink et al 1996). The contribution of each of these mechanisms to the outcomes obtained with tramadol is unknown.

In addition to norepinephrine and serotonin, dopamine plays a role in the descending inhibitory pain pathways at the supraspinal level of the thalamus, basal ganglia, and limbic cortex (Shyu et al 1992; Chudler and Dong 1995; Burkey et al 1999; Lopez-Avila et al 2004). An abnormal dopamine response to pain in patients with FM, which may be related to prolonged stress, has been reported (Wood et al 2007a). A disruption of dopaminergic neurotransmission being involved in the pathophysiology of FM has been further proposed due to a reduction of presynaptic dopamine metabolism, demonstrated by positron emission tomography, in these patients (Wood et al 2007b). In one RCT, the dopamine D3/D2 receptor agonist pramipexole reduced pain and improved fatigue and overall function as indicated by the FIQ score in patients with FM with no withdrawals from the study because of adverse effects (Holman and Myers 2005). However, as observed with other pharmacological treatments, pramipexole failed to evoke 50% or greater decrease in pain in all patients involved in the clinical trial with this efficacy level only being achieved in 42% of subjects. The patients in this trial, however, were taking their current medication,
which included opioid analgesics, making the study outcomes difficult to interpret. Ropinirole, another dopamine D3/D2 receptor agonist, failed to achieve a significant therapeutic response in patients with FM (Holman 2004); whether the lack of efficacy of ropinirole is independent of dopamine receptor modulation remains to be established.

**Alpha2-delta ligands**

The release of neurotransmitters that play a role in pain processing, such as glutamate and substance P, is regulated by calcium influx into nerve terminals within the nociceptive pathways (Millan 2002; Dooley et al 2007). Block of the presynaptic calcium channels by ligands of the α,δ subunit of that channel (eg, gabapentin, pregabalin) will decrease the neurotransmitter release and attenuate abnormal hyperexcitability of neuronal networks such as that associated with chronic pain. Functionally, α,δ-subunit ligands exhibit use-dependent properties giving these drugs a significant clinical advantage in that they will be expected to significantly modulate pathological functions related to maintained depolarization or hyperexcitability, but only minimally alter physiological synaptic function (Dooley et al 2007).

In patients with FM, gabapentin improved pain, FIQ, CGI, and PGI scores and sleep quality, however with a high incidence of adverse effects (eg, sedation, dizziness) (Arnold et al 2007a). Although a 30% or greater reduction in pain score was only achieved in 51% of gabapentin-treated patients, these findings support this concept as a therapeutic approach to FM. Pregabalin significantly reduced the pain score and improved sleep and fatigue in RCTs (of 8, 13, and 14 weeks) involving patients with FM, demonstrating efficacy against the three major symptoms of the condition (Crofford et al 2005; Arnold et al 2007b; Mease et al 2008). Although pregabalin monotherapy provides benefit in the management of FM as demonstrated by significantly more patients gaining 50% or greater improvement in pain with drug treatment than placebo treatment, this level of benefit was in a limited (up to 30%) number of subjects. The number of pregabalin responders only increased up to 50% of the subjects when an efficacy level of 30% or greater decrease in pain scores was determined. Further, little additional benefit, with an increase in the incidence of adverse effects, was conferred by the highest dose (600 mg/day) of pregabalin studied relative to that gained with the lower doses (300 and 450 mg/day) suggesting that in pregabalin-responders an efficacy ceiling was met (Crofford et al 2005; Arnold et al 2007b; Mease et al 2008).

The durability of the effects of pregabalin on pain, fatigue, and sleep disturbance was demonstrated in a 6-month, double-blind, placebo-controlled trial, with an onset of beneficial effects within 1 week of treatment (Crofford et al 2008). The durability of the treatment was determined by the time to loss of therapeutic response in patients who had previously demonstrated improvement in FM symptoms with pregabalin. At the end of the trial, 68% of drug-treated patients compared to 39% of placebo-treated patients maintained therapeutic response related to improvement in pain, sleep, fatigue, and functional status. Although more pregabalin- than placebo-treated patients discontinued due to adverse effects, pregabalin was well tolerated (Crofford et al 2008). Pregabalin has recently been approved by the FDA for the treatment of FM.

**Hypnotics**

Sedative hypnotics that modulate benzodiazepine receptors (BZD1 and BZD2) located on the GABA_A receptor complex have been evaluated in patients with FM (Arnold 2006; Lawson 2006a; Rooks 2007). The benzodiazepines, temazepam, alprazolam, and bromazepam, which act non-selectively at BZD receptors, have given inconsistent results in clinical trials in patients with FM. Although temazepam improved sleep quality, no concomitant improvement in pain or fatigue symptoms was observed (Hench et al 1989). Thus, a symptomatic benefit outcome was evoked by modulation of BZD receptors by benzodiazepines rather than management of the condition. Although benzodiazepines are useful in conditions involving neuronal hyperexcitability (eg, epilepsy, spasticity) and would be assumed to have the potential of controlling the pain related to the enhanced general sensitization in FM, acceptable efficacy has not been observed. Zolpidem and zopiclone, short-acting non-benzodiazepine hypnotics which interact preferentially with the BZD1 receptor, also improved sleep in patients with FM, but again failed to improve pain (Drewes et al 1991; Grönblad et al 1993; Moldofsky et al 1996). The failure of modulators of processes within the GABAergic inhibitory neurons to provide suppression of the symptoms of FM could suggest that the pathophysiology does not involve a state of hyperexcitability, but is related to an altered threshold of neuronal activation.

Sodium oxybate, the sodium salt of gamma-hydroxybutyrate (GHB), provided significant improvements in the major symptoms of FM (ie, pain, tenderness, sleep quality, and fatigue), which have been largely attributed to its capacity to consolidate and improve deep sleep (Russell et al 2005; Wood 2006). The improvement in pain, at least, being related to improved sleep is supported by the outcome of a significant correlation (r = 0.55, p < 0.001) between changes in
the pain scale and improvements in sleep quality. The specific processes responsible for the sleep disruption in FM are unclear. Sleep impacts on pain, fatigue, and social functioning (Schaefer 2003; Theadom et al 2007); nevertheless, it is not clear whether sleep disturbance is a symptom occurring itself or as a co-morbidity. It has been suggested that the relationship between pain and sleep may be bidirectional such that pain might increase sleep disturbance and disturbed sleep could intensify pain (Affleck et al 1996). Whether the pathophysiology for one symptom is responsible for the initiation of another symptom, or a single mechanism is concomitantly responsible for more than one symptom still requires determination. GHB is a precursor to GABA and exhibits agonist activity at the GABA$_B$ receptor and a postulated GHB-specific receptor (Maitre 1997). Data are awaited as to which, if any, is the primary mechanism responsible for the effectiveness and thereby beneficial outcomes with sodium oxybate in the management of FM (Mitler and Hayduk 2002).

**Pathophysiology**

A number of hypotheses have been proposed regarding the pathophysiology of FM, which includes a dysfunction of pain modulatory systems within the CNS, neuroendocrine dysfunction, and dysautonomia (Sarzi-Puttini et al 2006; Abeles et al 2007; Arendt Neilsen and Henriksson 2007; Tanriverdi et al 2007). FM is often described as a condition of heightened generalized sensitization to sensory input presenting as a complex of symptoms including pain, although lacking signs of underlying peripheral structural damage and inflammation. A cyclic model of the potential interrelationship of the proposed pathophysiological processes and the primary symptoms associated with FM is presented in Figure 1. Altered processing within the central nociceptive system is often proposed to be central to the manifestation of the condition and the typically experienced symptoms. As a consequence, pain has been described as both a symptom and a contributor of other symptoms such as fatigue, impairment of concentration, negative mood, degraded sleep, and diminished overall activity (Tuck and Dworkin 2004). Nevertheless, the nociceptive system is possibly one component of a complex network of physiological aspects that express a level of interdependence creating the clinical profile of FM. The cause of the interference in pain processing remains unclear, although involvement of

![Figure 1](image-url)
chronic psychological stressors, peripheral pain generators, and inflammatory mediators has been proposed (Bennett 2005; Abeles et al 2007).

Initiation of altered functioning of the nociceptive system has been related to a physical insult, leading to traumatized tissue and localized pain, or a psychological insult, such as stress (Figure 1) (Aaron et al 1997; Buskila et al 1997; Al-Allaf et al 2002; Tishler et al 2006). Sensitization of the central nociceptive system occurs due to such a sensory input. Central sensitization implies spontaneous nerve activity, expanded receptive fields, and abnormal temporal summation (or ‘wind-up’) within the spinal cord. NMDA receptors, found at the postsynaptic membrane in the dorsal horn of the spinal cord, are proposed to play a role in these phenomena. Once central (sensitization) hyperexcitability has been established, subsequent responses to normal stimuli are exaggerated and the threshold for the activation of new inputs is reduced. Central to a variety of neuronal processes, including synaptic plasticity and neurotoxicity, is the activation of NMDA receptors by glutamate leading to a rise in intracellular calcium and the initiation of second messenger pathways that mediate long-term potentiation (enduring enhancement of synaptic transmission after the initiating stimulus has ceased) (MacDermott et al 1986; Thomas 1995; Ressler et al 2002). In addition, nitric oxide production by neuronal nitric oxide synthase is induced by the calcium influx, which is believed to evoke a retrograde signaling action enhancing presynaptic glutamate release (DeMaria et al 2007). Studies on levels of nitric oxide in FM, however, have not been conclusive (Ozgocmen et al 2006). Similarly substance P, a peptide neurotransmitter associated with pain transmission, in addition to many other actions enhances the responsiveness of NMDA receptors to glutamate (DeMaria et al 2007). Although elevated levels of substance P in the cerebrospinal fluid of patients with FM have been reported (Vaerøy et al 1988; Russell et al 1994), such observations have not been confirmed in other studies. In patients with fibromyalgia temporal summation of nociceptive stimuli (where the intensity of rapidly repeated noxious stimuli is perceived to increase) is enhanced and diffuse noxious inhibitory control is reduced (Lautenbacher and Rollman 1997; Staud et al 2003; Julien et al 2005).

Studies utilizing neuroimaging techniques such as functional magnetic resonance imaging (fMRI), and single photon emission computed tomography (SPECT) have demonstrated that patients with FM exhibit neural activity in regions involved in processing the sensory pain sensation, in response to the administration of a noxious pressure or heat stimulus, that differs from that observed in health controls (Williams and Gracely 2006; Guedj et al 2007a). Although both patients with FM and healthy controls detect and experience a full range of perceived pain stimuli, the stimulus intensity threshold of the former group is significantly lower. The status of neural activity in the patients with FM was related to physiological and not psychological stimuli as mood states, such as depression, did not appear to influence the outcome. Data from SPECT neuroimaging studies have also been predictive of therapeutic responsiveness of treatment of patients with FM with amitriptyline and ketamine (Adiguzel et al 2004; Guedj et al 2007b). It is important to recognize that such neuroimaging techniques do not measure neural activity directly, but infer activity from localized changes in regional cerebral blood flow occurring in response to neural metabolic demand. Further work is required to determine whether these observations are related to neural demand influencing vascular status or whether a compromised vasculature, due to dysautonomia, is impacting on neural activity, or a combination of both. Neuroimaging has focused on the pain dimension of FM, where other symptoms such as fatigue and disturbed sleep have a significant role, as do non-noxious stimuli such as auditory and tactile (Geisser et al 2008).

The intensity and duration of the insult, and thereby pain, required to achieve the level of sensitization related to FM is not understood. Data from genetic studies could indicate a familial predisposition in vulnerable subjects to the development of FM (Buskila and Sarzi-Puttini 2006). Although the frequency of polymorphisms of the serotonin transporter promoter gene, 5-HT2A receptor gene, catechol-O-methyltransferase gene, and dopamine D4 receptor gene is changed in patients with FM, the relevance to the etiology and pathophysiology is unknown (Bondy et al 1999; Offenbaecher et al 1999; Cohen et al 2002; Gursoy et al 2003; Buskila et al 2004). Consequently what would be an innocuous event in the majority of the people has a marked outcome in 2%–4% of the population.

In addition to increasing the sensitivity of the central nociceptive system the sensory inputs appear to lead to activation of circuits of the limbic system such as the autonomic nervous system and the neuroendocrine hypothalamic pituitary adrenal (HPA) axis (Figure 1). HPA axis dysfunction in patients with FM is characterized by elevated cortisol levels lacking diurnal fluctuation with blunted secretion in response to stress (Abeles et al 2007; Tanriverdi et al 2007). This is consistent with the HPA axis being underactivated to stimuli and some patients with FM exhibiting a subnormal adrenocortical function. There are
no structural abnormalities in the endocrine glands of the HPA axis and current data do not allow an explanation of the location of the defect of the HPA dysfunction. Dysautonomia has also been suggested to be responsible for the generation and maintenance of the symptoms of FM (Martinez-Lavin 2007). Selective sympathetic blockade with guanethidine in patients with FM leads to a reduction in pain and number of tender points with restoration of the symptoms by norepinephrine injections (Backman et al 1988; Martinez-Lavin 2004). An increased sympathetic and decreased parasympathetic activity in patients with FM resulting in a persistently hyperactive sympathetic nervous system that is hyporeactive in response to stress has been reported (Martinez-Lavin et al 1997; Martinez-Lavin et al 1998; Cohen et al 2000). Chronic hyperstimulation of the α-adrenergic receptors of the sympathetic nervous system could lead to receptor desensitization and downregulation. The augmented sympathetic activity appears to be greater in women than men, suggesting that women with FM may have more severe autonomic dysfunction. Although TCAs and SNRIs, through modulation of bioamine levels, may achieve benefit in the treatment of FM by an effect on descending pain pathways, the lack of tolerance or efficacy of these drugs may be associated with an augmentation of the sympathetic component of the dysautonomia.

FM patients demonstrate significant variability in stress reactivity and the different response patterns related to potential autonomic response specificity (Turk and Flor 1989; Thieme et al 2006). The activation of the processes related to the limbic circuits in patients with FM appears to express an increased sensitivity to stressors perhaps due to the altered functioning preventing a normal physiological regulation of such an event and thereby exacerbation of certain systems. For example the limbic system, HPA axis, and autonomic nervous system activation could be related to mood arousal resulting in altered sleep architecture and enhanced anxiety leading to depression. Such outcomes within the limbic system may also be related to the memory and cognitive function, and mental fatigue (fibrofog) in patients with FM (Goldenberg et al 2008). The blunted sympathetic activity to stress and impaired parasympathetic modulation of the dysautonomia may also be associated with the prevalence of symptoms such as syncope, morning stiffness, pseudo-Raynaud’s phenomenon, and intestinal irritability observed in this patient population (Sarzi-Puttini et al 2006; Martinez-Lavin 2007).

Stress has central hyperalgesic effects that could be due to a direct central nociceptive system or an indirect peripheral action. The enhanced peripheral sympathetic nervous system tone related to the dysautonomia will, for example, lead to generalized widespread peripheral vasoconstriction (in addition to other autonomic responses). As a consequence of an associated reduced blood flow, a relatively mild challenge (eg, stretching, light exercise) to the skeletal muscle can evoke a state of ischemia and changed muscle energy metabolism. Low levels of phosphocreatine and ATP at rest, low phosphorylation potential, and total oxidative capacity, and a reduced number and size of mitochondria in skeletal muscle of patients with FM have been identified (Bengtsson et al 1986; Bartels and Danneskiold-Samsøe 1988; Jubrias et al 1994; McIver et al 2006). Such a vascular event would cause the sensitization of ergoreceptors, with the potential outcome of muscle fatigue, and the sensitization or activation of nociceptors leading to multifocal muscular pain and hyperalgesia well beyond the area of the initial physical insult. The generalized sensitization to pain within skeletal muscle will be associated with spatially distributed allodynia and hyperalgesia (tender points). Therefore, changes in peripheral factors, especially in intramuscular microcirculation and in muscle energy metabolism, could act as excitatory triggers for the alterations in the nociceptive system in the CNS and for multifocal pain in the muscles (Henriksson 1999; Abeles et al 2007). The activation of the nociceptors leading to further activation of the central nociceptive system will complete a loop within the processes related to the pathophysiological mechanisms of FM (Figure 1).

The potential of development of cyclic processes enables a trigger (eg, tender points, tissue trauma, exercise, stress) at any point within the loop to initiate and express (to varying degrees) the array of symptoms typical of FM. Evidence suggests patients with FM exhibit greater sensitivity to a range of sensory stimuli including auditory, tactile, heat, and pressure (Geisser et al 2003; Carrillo-de-la-Pena et al 2006; Montoya et al 2006; Geisser et al 2008). The heightened responsiveness to sensory stimulation may be related to a lack of inhibitory control over repetitive or irrelevant somatosensory stimulation (Geisser et al 2003; Carrillo-de-la-Pena et al 2006; Montoya et al 2006; Geisser et al 2008). These findings are consistent with FM being in part due to a global disturbance in sensory processing rather than an isolated abnormality in pain processing.

Conclusion

FM is a common, complex, and difficult to treat chronic widespread pain disorder, which usually requires a multidisciplinary approach using both pharmacological
and non-pharmacological interventions. It is described as a condition of heightened generalized sensitization to sensory input presenting as a complex of symptoms including pain, where the pathophysiology could include dysfunction of the CNS pain modulatory systems, dysfunction of the neuroendocrine system, and dysautonomia. Current data do not allow an understanding of the exact locations of the defects in these systems. In addition, whether aspects of the proposed pathophysiology are causal or consequential requires clarification. A cyclic model of the pathophysiological processes is compatible with the interrelationship of primary symptoms and the array of postulated triggers associated with FM.

Although a variety of treatment modalities have been utilized in the management of FM, an effective (>50% of the patient population gaining benefit) means of therapy is still awaited. Treatments have demonstrated an improvement in health status in a proportion of patients with FM in clinical trials; however, these findings require confirmation in usual-care settings of the subjects. Many of the molecular targets of current and emerging drugs used to treat FM have been focused to the management of discrete symptoms rather than the condition. Drugs (eg, pregabalin, duloxetine, milnacipran, sodium oxybate) have now been identified that demonstrate a multidimensional efficacy in this condition. The large percentage of patients who are refractory to these treatments during RCTs, makes it difficult to determine the relationship of the primary mechanism of action of the drugs to the pathophysiology of FM. Although the complexity of FM suggests that monotherapy, non-pharmacological or pharmacological, will not adequately address the condition, the outcomes from recent clinical trials are providing important clues for treatment guidelines, improved diagnosis, and condition-focused therapies. Finally, the diversity of the biology related to FM and the variability in responsiveness to treatments is consistent with the existence of subgroups of patients with potentially differing pathophysiology.

Disclosures

The author has no conflicts of interest to disclose.

References

Aaron LA, Bradley LA, Alarcon GS, et al. 1997. Perceived physical and emotional trauma as precipitating events in fibromyalgia: association with health care seeking and disability status but not pain severity. Arthritis Rheum, 40:453–60.
Abeles AM, Pillinger MH, Solitar BM, et al. 2007. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med, 146:726–4.
Adiguzel O, Kaptanoğlu E, Turgut B, et al. 2004. The possible effect of clinical recovery on regional cerebral blood flow deficits in fibromyalgia: a prospective study with semiquantitative SPECT. South Med J, 97:651–5.
Affleck G, Urrows S, Tennen H, et al. 1996. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia. Pain, 68:363–8.
Al-Allaf AW, Dunbar KL, Hallum NS, et al. 2002. A case-control study examining the role of physical trauma in the onset of fibromyalgia syndrome. Rheumatol, 41:450–3.
Al-Allaf AW, Ottewill L, Pullar T. 2002. The prevalence and significance of positive antinuclear antibodies in patients with fibromyalgia syndrome: 2–4 years’ follow-up. Clin Rheumatol, 1:472–7.
Anderberg UM, Marteinsdottir I, von Knorring L. 2000. Citalopram in patients with fibromyalgia – a randomized, double-blind, placebo-controlled study. Eur J Pain, 4:27–35.
Arendt Neilsen L, Henriksen KG. 2007. Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization and pain inhibition. Best Pract Res Clin Rheumatol, 21:465–80.
Arnold LM, Goldenberg DL, Stanford SB, et al. 2007a. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum, 56:1336–44.
Arnold LM, Hudson EV, Hudson JL, et al. 2002. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med, 112:191–7.
Arnold LM, Lu Y, Crofford Ll, et al. 2004. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum, 50:2974–84.
Arnold LM, Rosen A, Pritchett VL, et al. 2005. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with FM with or without major depressive disorder. Pain, 119:5–15.
Arnold LM, Russell JJ, Duan E, et al. 2007b. A 14-week, randomized, double-blind, placebo-controlled, monotherapy trial of pregabalin (BID) in patients with fibromyalgia syndrome (FMS). Annual Scientific Meeting of American Academy Neurology; www.ampainsoc.org/db2/abstract/view?poster_id=3119695 (accessed 17 May 2008).
Arnold LM. 2006. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther, 8:212.
Bäckman E, Bengtsson A, Bengtsson M, et al. 1988. Skeletal muscle function in primary fibromyalgia: effects of regional sympathetic blockade with guanethidine. Acta Neurol Scand, 77:187–91.
Baker K, Barkhuizen A. 2005. Pharmacologic treatment of fibromyalgia. Curr Pain Headache Rep, 9:301–6.
Baranuik JN, Whalen G, Cunningham J, et al. 2004. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord, 5:48.
Bartels EM, Dansneskiold-Samsoe B. 1988. Histological abnormalities in muscle from patients with certain types of fibrositis. Lancet, 1:755–7.
Bengtsson A, Henriksen KG, Larsson J. 1986. Muscle biopsy in primary fibromyalgia. Light-microscopical and histochemical findings. Scand J Rheumatol, 15:1–6.
Bennett R, Nelson D. 2006. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol, 2:416–24.
Bennett R. 2005. Fibromyalgia: present to future. Curr Rheum Rep, 7:371–6.
Bennett RM, Jones I, Turk DC, et al. 2007. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord, 8:27.
Bennett RM, Schein J, Kosinski MR, et al. 2005. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum, 53:519–27.
Bennett RM. 1998. Disordered growth hormone secretion in fibromyalgia: a review of recent findings and a hypothesized etiology. Z Rheumatol, 57(Suppl 2):72–6.
Bircan C, Karasel SA, Akgün B, et al. 2008. Effects of muscle strengthening versus aerobic exercise program in fibromyalgia. Rheumatol Int, 28:527–32.
Borody B, Spaeth M, Offenbaecher M, et al. 1999. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis, 6:433–9.
Burckhardt DC, Goldenberg D, Crofford L, et al. 2005. Guideline for the management of fibromyalgia syndrome pain in adults and children. In APS Clinical Practice Guidelines Series. No 4. Glenview, IL: American Pain Society.

Burkey AR, Carstens E, Jasmin L. 1999. Dopamine reuptake inhibition in the rostral agranular insular cortex produces antinociception. J Neurosci, 19:4169–79.

Busch AJ, Schachter CL, Overend TJ, et al. 2008. Exercise for fibromyalgia: a systematic review. J Rheumatol, 35:1130–44.

Buskila D, Cohen H, Neumann L, et al. 2004. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry, 9:730–1.

Buskila D, Neumann L, Vaisberg G, et al. 1997. Increased rates of fibromyalgia following cervical spine injury: a controlled study of 161 cases of traumatic injury. Arthritis Rheum, 40:446–52.

Buskila D, Sarzi-Puttini P. 2006. Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Res Ther, 8:218.

Carette S, Bell MJ, Reynolds WJ, et al. 1994. Comparison of amitriptyline, cyclobenzaprine and placebo in the treatment of fibromyalgia. Arthritis Rheum, 37:32–40.

Carette S, Oakson G, Guimont C, et al. 1995. Sleep electroencephalography and the clinical-response to amitriptyline in patients with fibromyalgia. Arthritis Rheum, 38:1211–7.

Carrillo-de-la-Peña MT, Vallet M, Pérez MI, et al. 2006. Intensity dependence of auditory-evoked cortical potentials in fibromyalgia patients: a test of the generalized hypervigilance hypothesis. J Pain, 7:480–7.

Carville SF, Arendt-Nielsen S, Bliddal H, et al. 2008. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis, 67:536–41.

Chudler EH, Dong WK. 1995. The role of the basal ganglia in nociception and pain. Pain, 60:3–38.

Clark S, Tindall E, Bennett RM. 1985. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol, 12:980–3.

Clark SR, Bennett R. 2000. Supplemental dextromethorphan in the treatment of FM. A double blind, placebo controlled study of efficacy and side effects. Arthritis Rheum, 43:S333.

Clauw DJ, Palmer RH, Thucker K, et al. 2007a. Milnacipran efficacy in the treatment of fibromyalgia syndrome: a 15-week randomized, double-blind, placebo-controlled trial. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting: November 6–11, 2007; Boston, MA. [Abstract #L1].

Clauw DJ, Palmer RH, Vinton O, et al. 2007b. The efficacy and safety of milnacipran in the treatment of fibromyalgia. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; November 6–11, 2007; Boston, MA. [Abstract #716].

Clauw DJ. 1995. Fibromyalgia: more than just a musculoskeletal disease. Am Fam Physician, 52:853–4.

Cohen H, Buskila D, Neumann L, et al. 2002. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum, 46:845–7.

Cohen H, Neumann L, Shore M, et al. 2000. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. Semin Arthritis Rheum, 29:217–27.

Cohen SP, Verdolin MH, Chang AS, et al. 2006. The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients. J Pain, 7:391–8.

Crofford LJ, Mease PJ, Simpson SL, et al. 2008. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month double-blind, placebo-controlled trial with pregabalin. Pain, 136:419–31.

Crofford LJ, Rowbotham MC, Mease PJ, et al. 2005. Pregabalin for the treatment of fibromyalgia syndrome. Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 52:1264–73.

DeMaria S, Hassett AL, Sigal LH, et al. 2007. N-Methyl-D-aspartate receptor-mediated chronic pain: new approaches to fibromyalgia syndrome etiology and therapy. J Musculoskeletal Pain, 15:33–44.

Desmeules JA, Cedraschi C, Rapiti, E, et al. 2003. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum, 48:1420–9.

Dooley DJ, Taylor CP, Donevan S, et al. 2007. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci, 28:75–82.

Drewes AM, Andreasen A, Jenum P, et al. 1991. Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol, 20:288–93.

Drexler AR, Mur EJ, Günther VC. 2002. Efficacy of an EMG-biofeedback therapy in fibromyalgia patients. A comparative study of patients with and without abnormality in (MMPI) psychological scales. Clin Exp Rheumatol, 20:677–82.

Frick MC, Hennies HH, Englerger W, et al. 1996. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung, 46:1029–36.

Geisser ME, Casey KL, Brucksh CB, et al. 2003. Perception of noxious and innocuous heat stimulation among healthy women and women with fibromyalgia: association with mood, somatic focus, and catastrophizing. Pain, 102:243–50.

Geisser ME, Glass JM, Rajcyska LD, et al. 2008. A psychophysical study of auditory and pressure sensitivity in patients with fibromyalgia and healthy controls. J Pain, 9:417–22.

Gendreau RM, Thom MD, Gendreau JF, et al. 2005. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol, 32:1975–85.

Goldenberg DL, Bradley LA, Arnold LM, et al. 2008. Understanding fibromyalgia and its related disorders. Prim Care Companion J Clin Psychiatry, 10:133–44.

Goldenberg DL, Clauw DJ, Palmer RH, et al. 2007. One-year durability of response to milnacipran treatment for fibromyalgia. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; November 6–11, 2007; Boston, MA. [Abstract #1526].

Goldenberg DL, Felson DT, Dinerman H. 1986. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum, 29:1371–7.

Goldenberg DL, Mayskiy M, Mossey C, et al. 1996. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum, 39:1852–9.

Goldenberg DL. 2007. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheum, 21:499–511.

Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, et al. 2000. Ketamine reduces muscle pain, temporal summation and referred pain in fibromyalgia patients. Pain, 85:483–91.

Grönblad M, Nykänen J, Konttinen Y, et al. 1993. Effect of zopiclone of pain, and without abnormality in (MMPI) psychological scales. Clin Exp Rheumatol, 20:677–82.

Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, et al. 2000. Ketamine reduces muscle pain, temporal summation and referred pain in fibromyalgia patients. Pain, 85:483–91.

Grönblad M, Nykänen J, Konttinen Y, et al. 1993. Effect of zopiclone of pain, and without abnormality in (MMPI) psychological scales. Clin Exp Rheumatol, 20:677–82.

Gürsöy S, Erdal E, Herken H. 2003. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int, 23:104–7.

Hammond A, Freeman K. 2006. Community patient education and exercise for people with fibromyalgia: a parallel group randomized controlled trial. Clin Rehabil, 20:835–46.

Harris RE, Clauw DJ, Scott DJ, et al. 2007. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci, 27:10000–6.
Hassan K, Radavinski DC, Vaschillo EG, et al. 2007. A pilot study of the efficacy of heart rate variability (HRV) biofeedback in patients with fibromyalgia. *Appl Psychophysiol Biofeedback*, 32:1–10.

Hench PK, Cohen R, Mitter MM. 1989. Fibromyalgia: effects of amitriptyline, temazepam and placebo on pain and sleep (abstract). *Arthritis Rheum*, 32:S47.

Henriksson KG. 1999. Is fibromyalgia a distinct clinical entity? Pain mechanisms in fibromyalgia syndrome. A myologist’s view. *Bailliere’s Best Pract Res Clin Rheumatol*, 13:455–61.

Hoffman DL, Dukes EM. 2008. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. *Int J Clin Pract*, 62:115–26.

Holman AJ, Myers RR. 2005. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. *Arthritis Rheum*, 52:2495–505.

Holman AJ. 2004. Treatment of fibromyalgia with the dopamine agonist ropinirole: a 14-week double-blind, pilot, randomized controlled trial with 14-week blinded extension. *Arthritis Rheum*, 50:S698.

Jain AK, Carruthers BM, van de Sande MI, et al. 2003. Fibromyalgia Syndrome: Canadian clinical working case definition, diagnostic and treatment protocols – a consensus document. *J Musculoskeletal Pain*, 11:13–10.

Jones KD, Adams D, Winters-Stone K, et al. 2006. A comprehensive review of 46 exercise treatment studies in fibromyalgia (1988–2005). *Health Qual Life Outcomes*, 4:67.

Jones KD, Burchhardt CS, Clark SR, et al. 2002. A randomized controlled trial of muscle strengthening versus flexibility training in fibromyalgia. *J Rheumatol*, 29:1041–8.

Jubrias SA, Bennett RM, Klug GA. 1994. Increased incidence of a resonance in the phosphodiester region of 31P nuclear magnetic resonance spectra in the skeletal muscle of fibromyalgia patients. *Arthritis Rheum*, 37:801–7.

Julien N, Goffaux P, Arsenault P, et al. 2005. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. *Pain*, 114:295–302.

Katz RS, Wolfe F, Michaud K. 2006. Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. *Arthritis Rheum*, 54:169–76.

Kendall SA, Bartels EM, Christensen R. 2004. A meta-analysis of cognitive-behavioural therapy in fibromyalgia. *J Musculoskeletal Pain*, 12(Suppl)49–56.

Kosek E, Hansson P. 1997. Modulatory influence on somatosensory perception from vibration and heterotropic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. *Pain*, 70:41–51.

Lautenbacher S, Rollman GB. 1997. Possible deficiencies of pain modulation in fibromyalgia. *Clin J Pain*, 13:189–96.

Lawson K, Shawcross E, Raphael JH. 2008. Function of potassium channels in blood mononuclear cells of patients with fibromyalgia. *J Pain Manage*, 1:in press.

Lawson K. 2002. Tricyclic antidepressants and fibromyalgia: what is the mechanism of action? *Expert Opin Invest Drugs*, 11:1437–45.

Lawson K. 2006a. Emerging pharmacological therapies for fibromyalgia. *Curr Opin Invest Drugs*, 7:631–6.

Lawson K. 2006b. Potassium channels as targets for the management of pain. *CNS Agents in Med Chem*, 6:119–28.

Lawson K. 2008. Pharmacological treatments of fibromyalgia: do complex conditions need complex therapies? *Drug Discov Today*, 13:333–40.

Lopez-Avila A, Coffeen U, Ortega-Legasi JM, et al. 2004. Dopamine and NMDA systems modulate long-term nociception in the rat anterior cingulated cortex. *Pain*, 111:136–43.

MacDermott AB, Mayer ML, Westbrook GL, et al. 1986. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurons. *Nature*, 321:519–22.

Maitre M. 1997. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. *Prog Neurobiol*, 51:337–61.
Rossy LA, Paschall G, Zhou XL, et al. 2002. Regulation of synaptic plasticity genes during consolidation of fear conditioning. J Neurosci, 22:7892–902.

Richeimer SH, Bajwa ZH, Kahranan SS, et al. 1997. Utilization patterns of tricyclic antidepressants in a multidisciplinary pain clinic: a survey. Clin J Pain, 13:324–9.

Rooks DS, Gautam S, Romeling M, et al. 2007. Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial. Arch Intern Med, 167:2192–200.

Rooks DS. 2007. Fibromyalgia treatment update. Curr Opin Rheumatol, 19:111–7.

Rossy LA, Buckelew SP, Dorr N, et al. 1999. A meta-analysis of fibromyalgia. Clin J Pain, 13:324–9.

Ritchie SH, Bajwa ZH, Kahranan SS, et al. 1997. Utilization patterns of tricyclic antidepressants in a multidisciplinary pain clinic: a survey. Clin J Pain, 13:324–9.

Ritcher LA, Buckelew SP, Dorr N, et al. 1999. A meta-analysis of fibromyalgia. Clin J Pain, 13:324–9.

Schaefer KM. 2003. Sleep disturbances linked to fibromyalgia. J Psychosom Res, 55:159–61.

Salemi S, Rethage J, Wolina U, et al. 2003. Detection of interleukin 1 beta (IL-1beta), IL-6 and tumour necrosis factor-alpha in skin in patients with fibromyalgia. J Rheumatol, 30:146–50.

Salemi S, Rethage J, Wolina U, et al. 2003. Detection of interleukin 1 beta (IL-1beta), IL-6 and tumour necrosis factor alpha in skin in patients with fibromyalgia. J Rheumatol, 30:146–50.

Sarzi-Puttini P, Atzeni F, Diana A, et al. 2006. Increased neural sympathetic activation in fibromyalgia syndrome. Ann Intern Med, 145:65–71.

Sarzi-Puttini P, Atzeni F, Diana A, et al. 2006. Increased neural sympathetic activation in fibromyalgia syndrome. Ann Intern Med, 145:65–71.

Shuto S, Takada H, Mochizuki D, et al. 1995. (3S,4R)-2-(Aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists. J Med Chem, 38:2964–9.

Shy BC, Kirsity-Roy JA, Morrow TJ, et al. 1992. Neurophysiological, pharmacological and behavioural evidence for medial thalamic mediation of cocaine-induced dopaminergic analgesia. Brain Res, 572:216–23.

Shy BC, Kirsity-Roy JA, Morrow TJ, et al. 1992. Neurophysiological, pharmacological and behavioural evidence for medial thalamic mediation of cocaine-induced dopaminergic analgesia. Brain Res, 572:216–23.

Stahl SM, Grady MM, Moret C, et al. 2005. SNRIs: their pharmacology, clinical efficacy and tolerability in comparison with other classes of antidepressants. CNS Spectrums, 10:732–47.

Staud R, Cannon RC, Mauderli AP, et al. 2003. Temporal summation of pain from mechanical stimulation of muscle tissue in controls and subjects with fibromyalgia syndrome. Pain, 102:87–95.

Tanriverdi F, Karaca Z, Unluhizarci K, et al. 2007. The hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. Stress, 10:13–25.

Theadom A, Crompton M, Humphrey KL. 2007. Exploring the role of sleep and coping in quality of life in fibromyalgia. J Psychosom Res, 62:145–51.

Thieme K, Rose U, Pinkpang T, et al. 2006. Psychophysiological responses in patients with fibromyalgia syndrome. J Psychosom Res, 61:671–9.

Thieme K, Turk DC, Flor H. 2007. Responder criteria for operant and cognitive-behavioral treatment of fibromyalgia syndrome. Arthritis Rheum, 57:830–6.

Thomas RJ. 1995. Excitatory amino acids in health and disease. J Am Geriatr Soc, 43:1279–89.

Turk DC, Dworkin RH. 2004. What should be the core outcomes in chronic pain clinical trials? Arthritis Rheum Ther, 6:151–4.

Turk DC, Flor H. 1989. Primary fibromyalgia is greater than tender points: toward a multiaxial taxonomy. J Rheumatol Suppl, 19:80–6.

Turk DC, Okifuji A, Sinclair JD, et al. 1996. Pain, disability, and physical functioning in subgroups of patients with fibromyalgia. J Rheumatol, 23:1255–62.

Turk DC, Okifuji A, Sinclair JD, et al. 1998. Interdisciplinary treatment for fibromyalgia syndrome: clinical and statistical significance. Arthritis Care Res, 11:186–95.

Vaeroy H, Helle R, Forre O, et al. 1988. Elevated cerebrospinal fluid levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain, 32:21–6.

Vitton O, Gendreau M, Gendreau J, et al. 2004. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Arthritis Rheum, 50:3277–85.

Williams DA, Gracey RH. 2006. Biology and therapy of fibromyalgia. Functional magnetic resonance imaging findings in fibromyalgia. Arthritis Res Ther, 8:224.

Wolfe F, Cathey MA, Hawley DJ. 1994. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol, 23:255–9.

Wolfe F, Smythe HA, Yunus MB, et al. 1990. The American College of Rheumatology (1990) criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum, 33:160–72.

Wolfe F, Zhao S, Lane N. 2000. Preference for non-steroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum, 43:378–85.

Wood PB, Patterson JC 2nd, Sunderland JJ, et al. 2007b. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with PET: a pilot study. J Pain, 8:51–8.

Wood PB, Schweinhardt P, Jaeger E, et al. 2007a. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci, 25:3576–82.

Wood PB. 2006. A randomized double-blind, placebo-controlled, parallel-group, multicenter trial comparing the effects of orally administered Xyrem (sodium oxybate) with placebo for the treatment of fibromyalgia. Pain Med, 7:181–2.

Yanus MB, Masi AT, Aldag JC. 1989. Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. J Rheumatol, 16:527–32.
